1. Home
  2. CUE vs ENTX Comparison

CUE vs ENTX Comparison

Compare CUE & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

N/A

Current Price

$3.99

Market Cap

177.0M

Sector

Health Care

ML Signal

N/A

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

N/A

Current Price

$3.15

Market Cap

147.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CUE
ENTX
Founded
2014
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
177.0M
147.4M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
CUE
ENTX
Price
$3.99
$3.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
★ $88.00
$9.75
AVG Volume (30 Days)
★ 304.8K
270.3K
Earning Date
11-16-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 61.11
N/A
EPS
N/A
★ 0.33
Revenue
★ $27,466,000.00
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$9.12
Revenue Growth
★ 195.75
N/A
52 Week Low
$0.17
$0.91
52 Week High
$45.50
$4.20

Technical Indicators

Market Signals
Indicator
CUE
ENTX
Relative Strength Index (RSI) 23.00 55.68
Support Level $0.22 $2.76
Resistance Level $33.95 $3.52
Average True Range (ATR) 2.70 0.19
MACD -1.38 -0.01
Stochastic Oscillator 6.25 42.54

Price Performance

Historical Comparison
CUE
ENTX

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: